3. Chelsea Therapeutics ( CHTP) ^NBI data by YCharts Chelsea shares started the year at well under $1, so it's spot among the best-performing biotech stocks is a bit misleading. Consider Chelsea's market is still only $170 million and that the stock price is down 50 percent from its level 18 months ago. But give Chelsea credit for perseverance. Despite a roller coaster development path, the company is poised to resubmit Northera to FDA later this summer as a treatment for neurogenic orthostatic hypotension.